Andrew Michael Kaz MD
Associate Professor, Medicine, University of Washington School of Medicine
Join to View Full Profile
1660 S. Columbian WayS-111-GastroSeattle, WA 98108
Phone+1 206-764-2285
Dr. Kaz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Andrew Kaz, MD is a gastroenterologist based in Seattle, WA, and serves as an Associate Professor at the UW Medicine/University of Washington Medical Center since 2019. He completed his medical education at Duke University, residency in Internal Medicine at the University of Michigan, and fellowship in Gastroenterology at the University of Washington. Dr. Kaz is experienced in esophageal disease, colonic neoplasms, and adenocarcinoma. His research includes several published studies, such as a notable contribution on the detection of esophageal adenocarcinoma and his involvement in multiple clinical trials, including those addressing treatments for GERD and colorectal cancer.
Education & Training
University of WashingtonFellowship, Gastroenterology, 2003 - 2007
University of MichiganResidency, Internal Medicine, 1999 - 2002
Duke University School of MedicineClass of 1999
Certifications & Licensure
WA State Medical License 2003 - 2026
MI State Medical License 1999 - 2006
American Board of Internal Medicine Gastroenterology
Clinical Trials
- Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Start of enrollment: 2012 Apr 30
- A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors Start of enrollment: 2012 Aug 13
- Optimal Treatment for Recurrent Clostridium Difficile Start of enrollment: 2015 Dec 21
Publications & Presentations
PubMed
- Emerging Biomarkers for Managing Barrett's Esophagus.Pakdee Rojanasopondist, Andrew Kaz, Ming Yu, William M Grady
Gastrointestinal Endoscopy Clinics of North America. 2026-01-01 - 2 citationsDiagnostic Methods and Biomarkers in Inflammatory Bowel Disease.Andrew M Kaz, Nanda Venu
Diagnostics. 2025-05-22 - 14 citationsBaseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a ...Douglas J Robertson, Jason A Dominitz, Alexander Beed, Kathy D Boardman, Barbara J Del Curto
JAMA Network Open. 2023-07-03
Press Mentions
Novel Barrett’s Esophagus Screening Assays Based on Swallowable Devices: Will They Change the Game?April 1st, 2019
Grant Support
- Methylated DNA Biomarkers For Barrett'S Esophagus And Esophageal AdenocarcinomaNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
